South Carolina CME Requirements and CME Courses

Get up to a $3,200 discount with a CMEinfo Insider subscription.

Features include:

• Earn unlimited AMA PRA Category 1 Credits^TM
• MOC Points
• 20+ Specialties

CMEinfo Insider offers online board reviews, journal summaries, and clinical updates.

The BoardVitals Addiction Medicine CME Review offers clinicians 40 AMA PRA Category 1 Credits^TM and over 700 Addiction Medicine board review questions. The questions cover key topics including recognition, intervention, and treatment of addiction. This question bank will assist clinicians with Addiction Medicine certification and recertification.

The BoardVitals Addiction Medicine CME Review  also features:

• Quick and Convenient CME
• Computer, phone, and tablet access
• Constantly updated up-to-date questions
• Questions that are targeted specifically to the exam
• Online CME tracker
• 100% Pass Guarantee
• Statistical comparison to other Addiction Medicine test-takers (Nationally)

After completing this activity, you should be able to:

• Identify the most commonly abused substances
• Recognize the most common indicators and symptoms of substance abuse and pain medicine dependency
• Describe the underlying pathophysiology of disease and basic science knowledge
• Formulate treatment for chronic pain management and substance abuse

Target Audience: Care providers concerned about issues of chronic pain and substance abuse.

According to the 2015 National Survey on Drug Use and Health, approximately 3.8 million people (1.4% of those ages 12 or older) reported misusing prescription pain relievers, while another 329,000 people reported using heroin. Within the same year, 52,404 lethal overdoses took place, making drug overdose the leading cause of accidental death within the United States. Stancliff et al estimated that as of 2012, approximately 80% of people dependent on heroin or prescription opioids were not engaged in any treatment and many in treatment do not use the most effective medication-assisted treatments available to them.

Despite recent increased awareness of opioid use disorder (OUD) and efforts to improve access to care, several barriers to treatment still exist, including financial, geographic, regulatory, and social. In 2012, only 2.2% of physicians in the United States obtained waivers to prescribe buprenorphine for the treatment of OUD. Of those who received waivers, 41.6% were psychiatrists. This may be perceived as a potential barrier to OUD treatment as patients are often resistant to referrals to psychiatric and/or addiction clinics given the stigmas commonly surrounding addiction and mental health. Furthermore, physicians with waivers were found to practice primarily in urban settings, leaving a large portion of the rural population without access to buprenorphine treatment.

With all this in mind, education is needed in regards to current and emerging treatment options for OUD available to multiple patient populations. Also, with the deaths due to drug overdoses still elevated, education on how to recognize and reverse an opioid overdose is needed.

This presentation will address the above needs by discussing the science behind opioid use disorder as well as reflect upon current statistics associated with its impact on the United States. During the discussion, opioid overdose risks will be discussed and participants will be able to practice recognizing key symptoms of an overdose situation. Steps of using naloxone will be discussed and connected to how to appropriately seek out treatment for maintenance of opioid use disorder. Finally, new buprenorphine products and the potential role of naltrexone will be applied to this stigmatized population.